Experts say the grim financial outlook for the few companies still committed to antibiotic research is driving away investors and threatening to strangle the development of new drugs.
Researchers investigated the mode of action of a new class of antibiotics that is highly effective against multidrug-resistant pathogens. Fibupeptides impair the energy supply to the bacterial cell, consequently causing their death.
Although new antibiotics are very much needed, they will only be most effective if they’re used sparingly — for the most critical of cases. This presents serious economic challenges to developing antibiotics.
Researchers, through testing, found the antibiotic to be very effective against E. coli, and carbapenem-resistant Enterobacter cloacae. It was effective against Mycobacterium bovis as well.
Researchers have developed a mathematical framework to estimate the value of investing in developing and conserving an antibiotic to mitigate the burden of bacterial infections caused by resistant Staphylococcus aureus during a pandemic influenza outbreak.
While the numbers of antibiotics annually approved for marketing in the US has increased following a decline in the previous decade, the authors found, the most recently approved drugs represent modifications to existing classes, rather than innovative approaches.
The US National Biodefense Strategy, released last year, highlights the need to reduce the emergence and spread of superbugs both domestically and internationally, and accelerate the development of new drugs, diagnostic tests, and vaccines.
Infections that were once easily treatable now require extraordinary doses of one or more antibiotics. Meanwhile, intravenous antibiotics with nicknames like “last resort” come off the shelf more and more often.
Researchers describe deoxy glycosides responsible for specific carbohydrate-phospholipid interactions, causing phosphatidylethanolamine lamellar-to-inverted hexagonal phase transition and acting over B. anthracis and Bacillus cereus as potent and selective bactericides.
Accepting that antibiotics are infrastructure would change our relationship to the drugs, forcing us to recognize that medicine requires long-term planning.